Pharmacy

Your Article Summary

See Latest Articles

FDA approves Micardis as the first treatment in its class to reduce the risk of heart attack, stroke, or death from cardiovascular causes in patients at high cardiovascular risk who are unable to take ACE inhibitors
Boehringer Ingelheim, 10/20/09

Boehringer Ingelheim announced that the US Food and Drug Administration has approved a new indication for Micardis for the reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major CV events who are unable to take ACE inhibitors. Micardis is the first treatment in its class to be approved for this indication.

Today in Cardiac/Hypertension...keeping you current

Receive free subspecialty "5-minute updates" via email

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy
Current Medical Research and Opinion, 11/20/09

See All of Cardiac/Hypertension

Today in Drug Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/22/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/10/09

See All of Drug Approvals